Previous 10 | Next 10 |
ContextLogic (NASDAQ:WISH) -27% on Q2 earnings release Cricut (NASDAQ:CRCT) -22% on Q2 earnings release Rigel Pharmaceuticals (NASDAQ:RIGL) -18% after FDA declines to approve fostamatinib COVID-19 EUA LifeMD (NASDAQ:LFMD) -13% on Q2 earnings release Sie...
BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three an...
MedAvail Holdings MDVL -34% on Q2 earnings release LifeStance Health LFST -24% on Q2 earnings release GoHealth GOCO -17% on Q2 earnings release VYNE Therapeutics VYNE -15% on Q2 earnings release and after BET inhibitor licensing deal with In4d...
BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug Administration...
Spectrum Pharmaceuticals SPPI -35% after FDA declines to approve ROLONTIS Dicerna Pharmaceuticals DRNA -28% slide despite pivotal nedosiran study hitting primary endpoint Zynga ZNGA -16% on Q2 earnings release Chembio Diagnostics CEMI -13% on Q2 earning...
Aprea Therapeutics (NASDAQ:APRE) shares slide more than 11% post market after the U.S. FDA places partial clinical hold on trials of eprenetapopt in combination with azacitidine in the company's myeloid malignancy programs. There are about 20 patients currently receiving eprenetapop...
BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug Administration...
Chembio Diagnostics (CEMI) +93% on receiving $28.3M purchase order from Bio-Manguinhos for DPP SARS-CoV-2. Antigen Tests in BrazilLexaria Bioscience (LEXX) +42% as DehydraTECH significantly enhances delivery of Colchicine in study VIRAL-A20-3.PainReform (PRFX) +27%.Xtant Medica...
58% relapse free survival at 1 year post-transplant 79% overall survival at 1 year post-transplant BOSTON, July 21, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics t...
CureVac (CVAC) -47% as Bill Gates-backed biotech shows below-par efficacy for COVID-19 vaccine candidate.Gaucho Group (VINO) -20%.Creatd (CRTD) -17% after proposing stock offeringNovan (NOVN) -14% after proposing capital raise.Torchlight Energy Resources (TRCH)...
News, Short Squeeze, Breakout and More Instantly...
Aprea Therapeutics Inc. Company Name:
APRE Stock Symbol:
NASDAQ Market:
Aprea Therapeutics Inc. Website:
DOYLESTOWN, Pa., June 21, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it will host a virtual KOL...
APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet medical need Dosing of the first patient in the ACESOT-1051 study represent...
ATRN-119 is the first and only macrocyclic ATR inhibitor in the clinic, with best in class potential On track to complete dose escalation in ABOYA-119 clinical trial and potentially generate initial human efficacy data in 2H 2024 Through the first 5 cohorts, ATRN-119 has been fo...